A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 Following Multiple Ascending Subcutaneous Dose Administration in Subjects With Dyslipidemia With or Without Type 2 Diabetes
Latest Information Update: 31 Dec 2021
At a glance
- Drugs AZD-8233 (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 15 Nov 2021 Results from a multiple ascending dose study of AZD8233 presented at the American Heart Association Scientific Sessions 2021
- 12 Nov 2021 According to an Ionis Pharmaceuticals media release, data from this study will be presented at the American Heart Association (AHA) Scientific Sessions, 2021
- 29 Jun 2021 Status changed from active, no longer recruiting to completed.